Microbot Medical Showcases LIBERTY Robotic System at ISET Conference

Reuters
Feb 12
Microbot Medical Showcases LIBERTY Robotic System at ISET Conference

Microbot Medical Inc. showcased its LIBERTY® Endovascular Robotic System at the International Symposium on Endovascular Therapy (ISET) conference held in Miami Beach, Florida, from February 9-12, 2026. During the event, the company participated in a Town Hall session focused on the future of endovascular robotics, where the LIBERTY System—currently the only FDA-cleared, single-use endovascular robotic system—was prominently featured. The system’s integration into clinical workflows and its role in advancing peripheral endovascular intervention were discussed by leading interventional specialists. This exposure is part of LIBERTY’s limited market release in the US, with plans for a full market launch later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653658-en) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10